| Name | Title | Contact Details |
|---|
At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial
At Blue Shield of California, we`re focused on fundamentally improving the ways in which members can access care and use their coverage. We`re investing in talented employees and new technologies to create an unrivaled member experience that elevates expectations and achieves our mission of making health care more accessible and affordable than ever. Today we are the third-largest health plan in the state and we`re dedicated to transforming the healthcare industry. Headquartered in San Francisco, with 18 additional offices across California, we`re proud to service over 4 million members and employ more than 6,000 people. We are an independent member of the Blue Shield Association. Blue Shield of California complies with applicable state laws and federal civil rights laws, and does not discriminate on the basis of race, color, national origin, ancestry, religion, sex, marital status, gender, gender identity, sexual orientation, age, or disability. Blue Shield of California cumple con las leyes estatales y las leyes federales de derechos civiles vigentes, y no discrimina por motivos de raza, color, país de origen, ascendencia, religión, sexo, estado civil, género, identidad de género, orientación sexual, edad ni discapacidad.
Clean Esd Products Inc is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Comhar, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.